ストックスクリーナーアプリを入手
2.63
0.75%
-0.02
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus
Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com
Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan
LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey
Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Lantern Pharma Inc. Revenue Breakdown – NASDAQ:LTRN - TradingView
LTRN|Lantern Pharma Inc|Price:2.750|Chg%:-0.120 - TradingKey
Lantern Pharma (LTRN) investor Thomas Satterfield discloses 7.6% stake and 975,000 shares - Stock Titan
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - BioSpace
Lantern Pharma receives patent allowance for LP-184 biomarker test - Investing.com
Lantern Pharma says USPTO allows patent application for LP-184 biomarker-guided solid tumor treatment methods - Bitget
LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Precision Oncology Pipeline - dars.gov.et
Lantern Pharma (LTRN) Slides 1.37% as Biotech Sector Faces HeadwindsSwing Entry Signals - dars.gov.et
New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group - ACCESS Newswire
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Business Wire
Lantern Pharma’s ZetaOmics turns plain-English questions into cancer analysis - Stock Titan
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Yahoo Finance
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance - The National Law Review
Lantern Pharma (LTRN) Holds Near Support Amid Modest Gains – Technical Levels in FocusSuperTrend - dars.gov.et
LTRN Forecast — Price Target — Prediction for 2027 - TradingView
Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN) - TradingView
LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseConsensus Beat Rate - dars.gov.et
[EFFECT] Lantern Pharma Inc. SEC Filing - Stock Titan
Lantern Pharma Inc (LTRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lantern Pharma Inc (LTRN) Institutional Confidence - TradingKey
Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lantern Pharma (LTRN) Edges Higher Amid Low Volume: Support and Resistance Levels in FocusWave Equality - DonanımHaber
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma (LTRN) Faces Pressure: Shares Dip 4.67% as Technical Support at $3.69 LoomsContinuation Pattern Picks - newsline.com
LTRN Q1 2026 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Remains KeyEarnings Surprise Score - newsline.com
Lantern Pharma (LTRN) Falls 4.7% as Biotech Stock Tests Key Support ZoneDividend Growth Stocks - newsline.com
Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk - Stock Titan
Lantern Pharma (LTRN) Extends Decline: Key Support Levels in Focus After 5.28% DropRisk Parity Rebalance - newsline.com
Lantern Pharma stock jumps on lung cancer trial survival data By Investing.com - Investing.com India
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - BioSpace
Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results - GuruFocus
Lantern Pharma stock jumps on lung cancer trial survival data - Investing.com
Lantern Pharma reports trial data for lung cancer treatment - Investing.com
Lantern Pharma reports trial data for lung cancer treatment By Investing.com - Investing.com Nigeria
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):